
The triple dilemma over India’s healthcare BPOs
Subscribe to enjoy similar stories. A laser-sharp focus on the US market in a world being reshaped by artificial intelligence has cast shadows over three Indian tech services companies catering to healthcare and life sciences companies. Lack of diversified businesses, policy uncertainty in the Donald Trump era, and the challenges of GenAI pose major risks for Sagility Ltd, Indegene Ltd, and Inventurus Knowledge Solutions Ltd, all of which listed on the stock exchanges in the past year, analysts said.
Most of their revenue comes from offering customer and software services to clients in the US healthcare sector. At least three experts are circumspect about the prospects of these companies because most of their revenue comes from offering customer and software services to clients in the US healthcare sector. “Hyper-specialized outsourcing firms such as Sagility and IKS Health present investors with a dilemma.
On the one hand, they allow them to play a single theme – large and underpenetrated US healthcare operational spend. On the other hand, risks of a potential downturn are unmitigated," JM Financial analysts Abhishek Kumar and Nandan Arekal said in a note dated 9 March, estimating the US healthcare market at about $200 billion. Queries emailed to all three companies remained unanswered at the time of publishing.
Bengaluru-based Sagility ended with $574 million in revenue last year, all of it from North America. Mumbai-based IKS, backed by the Jhunjhunwala family, got almost 98% of its $220 million revenue last year from North America. Indegene, which ended with $313 million in revenue, got 69% of it from the continent.
Read on livemint.com